Research Roundup

Debbie Rigby rounds up the latest in research news Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community Interim analyses from the PRINCIPLE trial shows that inhaled budesonide reduces time to recovery by a median of 3 days in people with COVID-19 with risk factors for adverse outcomes. Participants

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous A case of impairment
Next Coverage surpasses national goal